Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elodie Duray

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Frontiers in Immunology|May 28, 2020
Bispecific, T-Cell-Recruiting Antibodies in B-Cell MalignanciesMargaux Lejeune, Murat Cem Köse, Elodie Duray, et al.
Cancers|July 2, 2021
Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple MyelomaMargaux Lejeune, Elodie Duray, Matthias Peipp, et al.
EJNMMI Radiopharmacy and Chemistry|July 1, 2026
High-yield, standardised automated radiosynthesis process for routine clinical insulinoma PET with [⁶⁸Ga]Ga-NODAGA-exendin-4Elodie Duray, Matthieu Sacrez, Marine Hawotte, et al.
Leukemia & Lymphoma|June 3, 2017
Molecular mechanisms, current management and next generation therapy in myeloma bone diseaseRoy Heusschen, Joséphine Muller, Elodie Duray, et al.
Journal of Hematology & Oncology|November 3, 2021
A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myelomaElodie Duray, Margaux Lejeune, Frederic Baron, et al.
Frontiers in Immunology|July 22, 2022
Radiotheranostic Agents in Hematological MalignanciesJo Caers, Elodie Duray, Louise Vrancken, et al.
Hemasphere|June 26, 2023
Integrative Analysis of Proteomics and Transcriptomics Reveals Endothelin Receptor B as Novel Single Target and Identifies New Combinatorial Targets for Multiple MyelomaMargaux Lejeune, Murat Cem Köse, Mégane Jassin, et al.
British Journal of Haematology|April 2, 2020
The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour geneArnold Bolomsky, Joséphine Muller, Kathrin Stangelberger, et al.
Cancers|March 1, 2019
Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in OsteoclastsJoséphine Muller, Elodie Duray, Margaux Lejeune, et al.
Haematologica|May 12, 2018
Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone diseaseJoséphine Muller, Arnold Bolomsky, Sophie Dubois, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Frontiers in Immunology|May 28, 2020
Bispecific, T-Cell-Recruiting Antibodies in B-Cell MalignanciesMargaux Lejeune, Murat Cem Köse, Elodie Duray, et al.
Cancers|July 2, 2021
Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple MyelomaMargaux Lejeune, Elodie Duray, Matthias Peipp, et al.
EJNMMI Radiopharmacy and Chemistry|July 1, 2026
High-yield, standardised automated radiosynthesis process for routine clinical insulinoma PET with [⁶⁸Ga]Ga-NODAGA-exendin-4Elodie Duray, Matthieu Sacrez, Marine Hawotte, et al.
Leukemia & Lymphoma|June 3, 2017
Molecular mechanisms, current management and next generation therapy in myeloma bone diseaseRoy Heusschen, Joséphine Muller, Elodie Duray, et al.
Journal of Hematology & Oncology|November 3, 2021
A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myelomaElodie Duray, Margaux Lejeune, Frederic Baron, et al.
Frontiers in Immunology|July 22, 2022
Radiotheranostic Agents in Hematological MalignanciesJo Caers, Elodie Duray, Louise Vrancken, et al.
Hemasphere|June 26, 2023
Integrative Analysis of Proteomics and Transcriptomics Reveals Endothelin Receptor B as Novel Single Target and Identifies New Combinatorial Targets for Multiple MyelomaMargaux Lejeune, Murat Cem Köse, Mégane Jassin, et al.
British Journal of Haematology|April 2, 2020
The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour geneArnold Bolomsky, Joséphine Muller, Kathrin Stangelberger, et al.
Cancers|March 1, 2019
Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in OsteoclastsJoséphine Muller, Elodie Duray, Margaux Lejeune, et al.
Haematologica|May 12, 2018
Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone diseaseJoséphine Muller, Arnold Bolomsky, Sophie Dubois, et al.
Pageof 1